Bellicum Pharma (BLCM) Presents Early Phase 1 Results for BPX-601 Feb 16, 2023 07:30AM
Bellicum Presents Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO GU Cancers Symposium Feb 16, 2023 07:30AM
CORRECTION -- Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 31, 2023 06:43PM
Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) Jan 31, 2023 04:36PM
Bellicum Pharmaceuticals to Present Early Phase 1 Results for BPX-601 in Prostate Cancer at ASCO 2023 Genitourinary Cancers Symposium Jan 19, 2023 07:30AM


Dec 11, 2022 10:00AM Bellicum Announces Presentation by UNC at ASH 2022 on Potential Abrogation of iC9 CAR T-Cell Toxicities with Rimiducid
Nov 10, 2022 04:05PM Bellicum Reports Third Quarter 2022 Financial Results and Provides Operational Update
Oct 31, 2022 05:49PM Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Oct 4, 2022 07:30AM Bellicum Pharmaceuticals to Participate in the 2022 Cell & Gene Meeting on the Mesa
Oct 3, 2022 04:05PM Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 1, 2022 07:30AM Bellicum Pharmaceuticals to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Aug 11, 2022 04:02PM Bellicum Reports Second Quarter 2022 Financial Results and Provides Operational Update
Jul 1, 2022 07:30AM Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 12, 2022 04:05PM Bellicum Reports First Quarter 2022 Financial Results and Provides Operational Update
May 2, 2022 07:30AM Bellicum Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mar 24, 2022 04:05PM Bellicum Reports Fourth Quarter 2021 Financial Results and Provides Operational Update
Jan 26, 2022 04:05PM Bellicum Pharmaceuticals to Participate in the B. Riley Securities 2022 Virtual Oncology Conference
Dec 13, 2021 04:05PM Bellicum Regains Compliance with Nasdaq Continued Listing Requirements
Dec 6, 2021 07:31AM Bellicum Pharma (BLCM) Reports Positive Interim Data from Phase 1/2 GoCAR-T Studies, Announces 20.6M Share Private Placement at $1.70/sh
Dec 6, 2021 07:30AM Bellicum Announces Positive Interim Data from Phase 1/2 GoCAR-T® Studies, Secures $35 Million Private Placement Equity Financing Priced at Market
Nov 4, 2021 04:05PM Bellicum Reports Third Quarter 2021 Financial Results and Provides Operational Update
May 31, 2018 03:30AM Blockpass launches Token Distribution Event
Apr 17, 2018 09:22AM Pre-Open Movers 04/17: (RNDA) (ROKU) (NFLX) Higher; (BLCM) (LADR) (SEAC) Lower (more...)
Jan 22, 2018 09:29AM Pre-Open Movers 01/22: (BIVV) (JUNO) (ARRY) Higher; (SANM) (TEVA) (TWTR) Lower (more...)
Jan 17, 2018 09:11AM Blockpass IDN announces Key Memberships with DIF, Trusted IOT Alliance
Oct 14, 2016 08:30AM Cancer Immunotherapy ETF Celebrates One-Year Anniversary
Aug 10, 2016 06:08AM BioLife Solutions (BLFS), Bellicum Pharmaceuticals (BLCM) Enter CryoStor Supply Agreement
Jul 20, 2016 07:10AM Bellicum Pharma (BLCM) Announces Issuance of US Patent Covering CaspaCIDe Cell Therapy Method
Jul 20, 2016 07:00AM Bellicum Pharmaceuticals Announces Patent on CaspaCIDe Method for Selectively Eliminating Therapeutic Cells
Aug 5, 2015 07:00AM Bellicum Pharmaceuticals Announces Patent Issued on Methods for Inducing Selective Apoptosis for its Lead Product Candidate BPX-501